{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:25:11Z","timestamp":1794565511828,"version":"4.9.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["R01 DA037897"],"award-info":[{"award-number":["R01 DA037897"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["R01 DA061799"],"award-info":[{"award-number":["R01 DA061799"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["R21 DA045792"],"award-info":[{"award-number":["R21 DA045792"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopsych.2026.05.002","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:55:30Z","timestamp":1778889330000},"page":"862-874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preclinical and Emerging Clinical Evidence Supporting the Translational Potential of GLP-1 Receptor Agonists for Treating Psychostimulant and Nicotine Use Disorders"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6119-3027","authenticated-orcid":false,"given":"Rae J.","family":"Herman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5604-8239","authenticated-orcid":false,"given":"Antonia","family":"Caffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9420-8884","authenticated-orcid":false,"given":"Austin","family":"Pothikamjorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Petrilli","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0646-5605","authenticated-orcid":false,"given":"Heath D.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2026.05.002_bib3","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a040311","article-title":"The persistent challenge of developing addiction pharmacotherapies","volume":"11","author":"Swinford-Jackson","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.biopsych.2026.05.002_bib4","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/07853890.2012.705016","article-title":"Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis","volume":"44","author":"Mills","year":"2012","journal-title":"Ann Med"},{"key":"10.1016\/j.biopsych.2026.05.002_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.physbeh.2019.03.026","article-title":"Central GLP-1 receptors: Novel molecular targets for cocaine use disorder","volume":"206","author":"Hernandez","year":"2019","journal-title":"Physiol Behavior"},{"key":"10.1016\/j.biopsych.2026.05.002_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114565","article-title":"Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence","volume":"281","author":"Herman","year":"2024","journal-title":"Physiol Behav"},{"key":"10.1016\/j.biopsych.2026.05.002_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2026.05.002_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069010","article-title":"The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2026.05.002_bib9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/mp.2012.141","article-title":"GLP-1 analog attenuates cocaine reward","volume":"18","author":"Graham","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.05.002_bib10","article-title":"Glucagon-like peptide-1 analog exendin-4 ameliorates cocaine-mediated behavior by inhibiting Toll-like receptor 4 signaling in mice","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.biopsych.2026.05.002_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol Behav"},{"key":"10.1016\/j.biopsych.2026.05.002_bib12","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.ijo.0803284","article-title":"Antiobesity action of peripheral exenatide (exendin-4) in rodents: Effects on food intake, body weight, metabolic status and side-effect measures","volume":"30","author":"Mack","year":"2006","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.biopsych.2026.05.002_bib13","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","article-title":"The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide","volume":"62","author":"Kanoski","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.biopsych.2026.05.002_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2025.07.001","article-title":"Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens","volume":"98","author":"Aran\u00e4s","year":"2025","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2026.05.002_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2026.106219","article-title":"Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents","volume":"126","author":"Edvardsson","year":"2026","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopsych.2026.05.002_bib17","article-title":"Effects of glucagon-like peptide-1 receptor agonist exendin-4 on the reinstatement of cocaine-mediated conditioned place preference in mice","volume":"15","author":"Zhu","year":"2021","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.biopsych.2026.05.002_bib18","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/adb.12583","article-title":"Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats","volume":"24","author":"Hernandez","year":"2019","journal-title":"Addict Biol"},{"key":"10.1016\/j.biopsych.2026.05.002_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.86","article-title":"Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels","volume":"6","author":"Reddy","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2026.05.002_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.physbeh.2017.03.019","article-title":"Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core","volume":"176","author":"Fortin","year":"2017","journal-title":"Physiol Behav"},{"key":"10.1016\/j.biopsych.2026.05.002_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr5051","article-title":"An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking","volume":"11","author":"Merkel","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.biopsych.2026.05.002_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopsych.2026.05.002_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2337\/db14-0668","article-title":"GLP-1 and exendin-4 transiently enhance GABAA receptor-mediated synaptic and tonic currents in rat hippocampal CA3 pyramidal neurons","volume":"64","author":"Korol","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.biopsych.2026.05.002_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2026.05.002_bib26","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamapediatrics.2024.3812","article-title":"Risk of suicidal ideation or attempts in adolescents with obesity treated with GLP1 receptor agonists","volume":"178","author":"Kerem","year":"2024","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.biopsych.2026.05.002_bib27","first-page":"659","article-title":"FDA requests removal of suicidal ideation warning from GLP-1 RA medications","volume":"335","author":"Anderer","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2026.05.002_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.neuropharm.2018.01.048","article-title":"Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?","volume":"136","author":"Mansur","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nat Ment Health"},{"key":"10.1016\/j.biopsych.2026.05.002_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100916","article-title":"Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial","volume":"7","author":"Badulescu","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.biopsych.2026.05.002_bib31","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/j.1460-9568.1995.tb00650.x","article-title":"Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites","volume":"7","author":"Goke","year":"1995","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.biopsych.2026.05.002_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system","volume":"403","author":"Merchenthaler","year":"1999","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.biopsych.2026.05.002_bib33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib34","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/npp.2015.362","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area decreases the reinforcing efficacy of cocaine","volume":"41","author":"Schmidt","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib35","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1038\/s41380-020-00957-3","article-title":"GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA","volume":"26","author":"Hernandez","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.05.002_bib36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1749-6632.2009.05144.x","article-title":"Cocaine-induced neuroadaptations in glutamate transmission: Potential therapeutic targets for craving and addiction","volume":"1187","author":"Schmidt","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.biopsych.2026.05.002_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/en.2014-1675","article-title":"Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain","volume":"156","author":"Heppner","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib38","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1523\/JNEUROSCI.3262-11.2011","article-title":"Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake","volume":"31","author":"Dossat","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2026.05.002_bib39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cobeha.2016.02.005","article-title":"GLP-1 influences food and drug reward","volume":"9","author":"Hayes","year":"2016","journal-title":"Curr Opin Behav Sci"},{"key":"10.1016\/j.biopsych.2026.05.002_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105702","article-title":"The mesopontine tegmentum in reward and aversion: From cellular heterogeneity to behaviour","volume":"162","author":"Bastos-Goncalves","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2026.05.002_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0361-9230(90)90072-8","article-title":"Afferent and efferent connections of the laterodorsal tegmental nucleus in the rat","volume":"25","author":"Cornwall","year":"1990","journal-title":"Brain Res Bull"},{"issue":"Pt B","key":"10.1016\/j.biopsych.2026.05.002_bib42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.neuropharm.2013.04.031","article-title":"Neurocircuitry of drug reward","volume":"76","author":"Ikemoto","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/cne.20417","article-title":"Laterodorsal tegmental projections to identified cell populations in the rat ventral tegmental area","volume":"483","author":"Omelchenko","year":"2005","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.biopsych.2026.05.002_bib44","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1073\/pnas.0510715103","article-title":"The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neurons","volume":"103","author":"Lodge","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2026.05.002_bib45","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1046\/j.1460-9568.2000.00250.x","article-title":"Laterodorsal tegmental stimulation elicits dopamine efflux in the rat nucleus accumbens by activation of acetylcholine and glutamate receptors in the ventral tegmental area","volume":"12","author":"Forster","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.biopsych.2026.05.002_bib46","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1460-9568.2009.06904.x","article-title":"The limbic circuitry underlying cocaine seeking encompasses the PPTg\/LDT","volume":"30","author":"Schmidt","year":"2009","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.biopsych.2026.05.002_bib47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ejn.13436","article-title":"Optogenetic excitation in the ventral tegmental area of glutamatergic or cholinergic inputs from the laterodorsal tegmental area drives reward","volume":"45","author":"Steidl","year":"2017","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.biopsych.2026.05.002_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature11527","article-title":"Input-specific control of reward and aversion in the ventral tegmental area","volume":"491","author":"Lammel","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2026.05.002_bib49","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neuropharm.2014.01.019","article-title":"Critical role of cholinergic transmission from the laterodorsal tegmental nucleus to the ventral tegmental area in cocaine-induced place preference","volume":"79","author":"Shinohara","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbr.2015.02.049","article-title":"Increased latencies to initiate cocaine self-administration following laterodorsal tegmental nucleus lesions","volume":"287","author":"Steidl","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2026.05.002_bib51","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/npp.2017.225","article-title":"Glucagon-like peptide-1 receptor signaling in the lateral dorsal tegmental nucleus regulates energy balance","volume":"43","author":"Reiner","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.brainres.2010.03.059","article-title":"Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure","volume":"1350","author":"Rinaman","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2026.05.002_bib53","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/npp.2015.47","article-title":"Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior","volume":"40","author":"Harasta","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.drugalcdep.2017.07.033","article-title":"Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses","volume":"180","author":"Bouhlal","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2026.05.002_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2026.05.002_bib56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ADM.0000000000001147","article-title":"Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: A case series study","volume":"17","author":"Yammine","year":"2023","journal-title":"J Addict Med"},{"key":"10.1016\/j.biopsych.2026.05.002_bib57","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.physbeh.2012.03.014","article-title":"Exendin-4 decreases amphetamine-induced locomotor activity","volume":"106","author":"Erreger","year":"2012","journal-title":"Physiol Behav"},{"key":"10.1016\/j.biopsych.2026.05.002_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.109872","article-title":"The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder","volume":"99","author":"Chaves Filho","year":"2020","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.05.002_bib59","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.physbeh.2016.04.013","article-title":"Central and peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors","volume":"161","author":"Sirohi","year":"2016","journal-title":"Physiol Behav"},{"key":"10.1016\/j.biopsych.2026.05.002_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077284","article-title":"The glucagon-like peptide 1 analogue exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2026.05.002_bib61","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","article-title":"Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats","volume":"240","author":"Herman","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2026.05.002_bib62","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2026.05.002_bib63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40429-019-00253-3","article-title":"Tobacco smoking, eating behaviors, and body weight: A review","volume":"6","author":"Chao","year":"2019","journal-title":"Curr Addict Rep"},{"key":"10.1016\/j.biopsych.2026.05.002_bib64","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/clpt.2011.105","article-title":"Cigarette smoking, nicotine, and body weight","volume":"90","author":"Audrain-McGovern","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2026.05.002_bib65","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1037\/0022-006X.65.3.448","article-title":"Are weight concerns predictive of smoking cessation? A prospective analysis","volume":"65","author":"Meyers","year":"1997","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.biopsych.2026.05.002_bib66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbrc.2021.12.064","article-title":"A mouse model of weight gain after nicotine withdrawal","volume":"588","author":"Takeda","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.biopsych.2026.05.002_bib67","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/17460441.2014.908180","article-title":"Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal","volume":"9","author":"Ashare","year":"2014","journal-title":"Expert Opinn Drug Discov"},{"key":"10.1016\/j.biopsych.2026.05.002_bib68","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-010-1848-1","article-title":"Meta-analysis of the acute effects of nicotine and smoking on human performance","volume":"210","author":"Heishman","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2026.05.002_bib69","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-13482-6_4","article-title":"Nicotine withdrawal","volume":"24","author":"McLaughlin","year":"2015","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.biopsych.2026.05.002_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/20451253251396304","article-title":"Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: A systematic review","volume":"15","author":"Lee","year":"2025","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.biopsych.2026.05.002_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112466","article-title":"GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity","volume":"42","author":"Falk","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.biopsych.2026.05.002_bib72","doi-asserted-by":"crossref","first-page":"9124","DOI":"10.1073\/pnas.1220591110","article-title":"Reinstatement of nicotine seeking is mediated by glutamatergic plasticity","volume":"110","author":"Gipson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2026.05.002_bib73","first-page":"169","article-title":"Neurobiological and neurophysiological mechanisms underlying nicotine seeking and smoking relapse","volume":"4","author":"Schmidt","year":"2019","journal-title":"Mol Neuropsychiatry"},{"key":"10.1016\/j.biopsych.2026.05.002_bib74","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.neuron.2017.09.042","article-title":"Enhanced AMPA receptor trafficking mediates the anorexigenic effect of endogenous glucagon-like peptide-1 in the paraventricular hypothalamus","volume":"96","author":"Liu","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2026.05.002_bib75","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1152\/ajpendo.00413.2013","article-title":"The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA\/kainate receptors","volume":"305","author":"Mietlicki-Baase","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.05.002_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2014.04.003","article-title":"Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex","volume":"190\u2013191","author":"Ohtake","year":"2014","journal-title":"Regul Pept"},{"key":"10.1016\/j.biopsych.2026.05.002_bib77","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1042\/BST20150244","article-title":"The complexity of signalling mediated by the glucagon-like peptide-1 receptor","volume":"44","author":"Fletcher","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.biopsych.2026.05.002_bib78","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nature09797","article-title":"Habenular \u03b15 nicotinic receptor subunit signalling controls nicotine intake","volume":"471","author":"Fowler","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2026.05.002_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.yhbeh.2023.105447","article-title":"Acute nicotine intake increases feeding behavior through decreasing glucagon signaling in dependent male and female rats","volume":"159","author":"Shankar","year":"2024","journal-title":"Horm Behav"},{"key":"10.1016\/j.biopsych.2026.05.002_bib80","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41467-018-04654-2","article-title":"Nicotine aversion is mediated by GABAergic interpeduncular nucleus inputs to laterodorsal tegmentum","volume":"9","author":"Wolfman","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.biopsych.2026.05.002_bib81","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: A pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.biopsych.2026.05.002_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: A single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopsych.2026.05.002_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102429","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial","volume":"68","author":"L\u00fcthi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopsych.2026.05.002_bib84","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2026.05.002_bib85","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1111\/bph.70096","article-title":"A GLP-1R\/Y(1) receptor\/Y(2) receptor triple agonist decreases fentanyl-evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats","volume":"182","author":"Caffrey","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2026.05.002_bib86","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamapsychiatry.2025.4308","article-title":"Prospects of GLP-1 therapies for addiction and mental health comorbidities-quo vadis?: A review","volume":"83","author":"Farokhnia","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.05.002_bib87","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40120-025-00724-y","article-title":"Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: A narrative review [published correction appears in Neurol Ther 2025;14:1167]","volume":"14","author":"West","year":"2025","journal-title":"Neurol Ther"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326012746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326012746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:49:22Z","timestamp":1794563362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322326012746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":85,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0006322326012746"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.05.002","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical and Emerging Clinical Evidence Supporting the Translational Potential of GLP-1 Receptor Agonists for Treating Psychostimulant and Nicotine Use Disorders","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}